1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Eight patients who had subdural collections on MR imaging within 7 days after LP^{^a}
Presenting Diagnosis/Reason for Procedure Age (yr) Days between LP and MR Imaging CSF Removed (mL) CSF Opening Pressure (cm H₂O) Brain Sag Venous Distension Diffuse Dural Enhancement
Patient 1 Mycosis fungoides 35 4 9 NA Yes Yes Yes
Patient 2 Leukemia 42 4 8 NA No Yes Yes
Patient 3 AMS 54 3 16 NA No No Yes
Patient 4 AMS 61 0 14 NA No No No
Patient 5 Multiple myeloma 69 3 16 NA No No Yes
Patient 6 Leukemia 69 1 6 NA No No No
Patient 7 Pulmonary adenocarcinoma 69 6 15 13 No No Yes
Patient 8 AMS 71 4 14 14 No No Yes
Note:—NA indicates not available; AMS, altered mental status.
↵a None of the patients had a definite etiology on CSF analysis to explain dural enhancement. Each patient underwent an LP with a 22-ga Quincke tip spinal needle.